Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Although the global emergency phase of COVID-19 has subsided, optimizing vaccination strategies for immunocompromised populations remains a public health priority. Patients with end-stage kidney disease (ESKD) are known to have impaired immune responses. This study evaluated and compared humoral immune responses following booster vaccination with full- versus half-dose mRNA-1273 in ESKD and non-dialysis cohorts primed with ChAdOx1 nCoV-19.
In this prospective observational study, 242 ESKD patients received two doses of ChAdOx1 nCoV-19 followed by a full-dose (100 μg) mRNA-1273 booster. The control group comprised 271 non-dialysis individuals who received the same priming series followed by a half-dose (50 μg) mRNA-1273 booster, as recommended by Taiwan national guidelines. SARS-CoV-2 IgG antibody titers were quantified.
Seropositivity following the second dose was observed in 47.2% of ESKD patients (33.64 ± 91.40 AU/mL) and 68.7% of controls (29.63 ± 47.94 AU/mL). After the booster, ESKD patients had significantly higher antibody titers than controls (221.56 ± 379.53 vs. 56.56 ± 47.39 AU/mL; p = 0.0015). Older age was associated with a diminished response (OR = 0.973, 95% CI: 0.959–0.989; p < 0.001), while a longer interval between vaccine doses enhanced response (OR = 1.028 per day, 95% CI: 1.011–1.046; p = 0.001). The second dose significantly improved seroconversion (OR = 2.115; p < 0.001), and the booster induced a 25-fold antibody increase (OR = 25.257; p < 0.001). Among ESKD patients, responders had higher hemoglobin levels than non-responders (11.07 ± 1.47 vs. 10.43 ± 1.67 g/dL; p = 0.0447). Significant interaction effects between pre-vaccination antibody levels and booster response were observed in both continuous (β = 869.40; p = 0.0004) and categorical (β = 697.74; p = 0.0002) models.
A full-dose mRNA-1273 booster significantly enhances humoral immunity in ESKD patients primed with ChAdOx1 nCoV-19, yielding higher post-booster titers than half-dose strategies in non-dialysis individuals. These findings support the need for tailored booster regimens in vulnerable populations.
